CONTEXT: In clinical pancreas transplantation the choice of preservation solution may have an impact on graft pancreatitis. Experience with histidine-tryptophan-ketoglutarate (HTK) is still limited whereas University of Wisconsin (UW) solution is currently the preferred perfusate worldwide. OBJECTIVE: The aim of this study was to analyze our experience with HTK in pancreas transplantation. PARTICIPANTS: In a retrospective analysis, data from 95 primary simultaneous pancreas-kidney transplantations were reviewed. The use of HTK (n=48) and UW (n=47) solution was stratified into two groups. MAIN OUTCOME MEASURES: Patient/graft survival and early graft function were compared. RESULTS: No significant differences between 1, 3 and 12 month patient survival (HTK: 97.9%, 97.9%, and 95.7% vs. UW: 95.7%, 89.4%, and 89.4%, respectively), and pancreas graft survival (HTK: 87.5%, 87.5%, and 85.4% vs. UW: 87.0%, 82.6%, and 82.6%, respectively) were detected. Higher values for peak lipase were observed on day 1 in the HTK group (not reaching significance: P=0.131) whereas no differences were noted for amylase and C-reactive protein. CONCLUSIONS: HTK is clinically comparable to UW. Both solutions have been shown to be safe for pancreas preservation. Successful pancreas transplantation depends on many factors such as donor and recipient factors, but skilled organ procurement techniques, organ preservation, and transplant experience in this field is mandatory. The choice of organ preservation solution is only one point in this context.
CONTEXT: In clinical pancreas transplantation the choice of preservation solution may have an impact on graft pancreatitis. Experience with histidine-tryptophan-ketoglutarate (HTK) is still limited whereas University of Wisconsin (UW) solution is currently the preferred perfusate worldwide. OBJECTIVE: The aim of this study was to analyze our experience with HTK in pancreas transplantation. PARTICIPANTS: In a retrospective analysis, data from 95 primary simultaneous pancreas-kidney transplantations were reviewed. The use of HTK (n=48) and UW (n=47) solution was stratified into two groups. MAIN OUTCOME MEASURES: Patient/graft survival and early graft function were compared. RESULTS: No significant differences between 1, 3 and 12 month patient survival (HTK: 97.9%, 97.9%, and 95.7% vs. UW: 95.7%, 89.4%, and 89.4%, respectively), and pancreas graft survival (HTK: 87.5%, 87.5%, and 85.4% vs. UW: 87.0%, 82.6%, and 82.6%, respectively) were detected. Higher values for peak lipase were observed on day 1 in the HTK group (not reaching significance: P=0.131) whereas no differences were noted for amylase and C-reactive protein. CONCLUSIONS: HTK is clinically comparable to UW. Both solutions have been shown to be safe for pancreas preservation. Successful pancreas transplantation depends on many factors such as donor and recipient factors, but skilled organ procurement techniques, organ preservation, and transplant experience in this field is mandatory. The choice of organ preservation solution is only one point in this context.
Authors: Nicholas Latchana; Joshua R Peck; Bryan A Whitson; Mitchell L Henry; Elmahdi A Elkhammas; Sylvester M Black Journal: World J Transplant Date: 2015-12-24
Authors: Peter Thomas Fellmer; Andreas Pascher; Andreas Kahl; Frank Ulrich; Katharina Lanzenberger; Konstanze Schnell; Sven Jonas; Stefan G Tullius; Peter Neuhaus; Johann Pratschke Journal: Langenbecks Arch Surg Date: 2010-01 Impact factor: 3.445
Authors: M Maglione; R Oberhuber; B Cardini; K Watschinger; M Hermann; P Obrist; P Hengster; W Mark; S Schneeberger; G Werner-Felmayer; J Pratschke; R Margreiter; E R Werner; G Brandacher Journal: Am J Transplant Date: 2010-10 Impact factor: 8.086
Authors: Daniel H Paushter; Meirigeng Qi; Kirstie K Danielson; Tricia A Harvat; Katie Kinzer; Barbara Barbaro; Sonny Patel; Sarah Z Hassan; Jose Oberholzer; Yong Wang Journal: Cell Transplant Date: 2012-10-02 Impact factor: 4.064
Authors: Yasuhiro Iwanaga; David Er Sutherland; James V Harmon; Klearchos K Papas Journal: Curr Opin Organ Transplant Date: 2008-08 Impact factor: 2.640
Authors: Dawit Worku; Sebastian Laluf; Jennifer McGee; Monica Goswami; Keith VanMeter; Douglas P Slakey Journal: J Surg Res Date: 2009-10-01 Impact factor: 2.192
Authors: R Oberhuber; P Ritschl; C Fabritius; A-V Nguyen; M Hermann; P Obrist; E R Werner; M Maglione; B Flörchinger; S Ebner; T Resch; J Pratschke; K Kotsch Journal: Am J Transplant Date: 2015-06-23 Impact factor: 8.086